Antibody-drug conjugate · Cytotoxic, directed at PD-L1 (CD274) · developed by Pfizer
Fetrastobart vedotin is an antibody-drug conjugate in which an antibody against PD-L1 is linked to the cytotoxic agent MMAE through a protease-cleavable linker. After binding PD-L1 on tumor cells and internalization, MMAE is released, inhibits microtubule polymerization and induces cell cycle arrest and apoptosis. It is being studied in non-small cell lung cancer.
Summary written with AI from the sources listed at the end of this page.
Non-small Cell CarcinomaNon-Small Cell Lung Cancer MetastaticNon-Small Cell Lung Carcinoma
Updated Nov 8, 2026. Something wrong or missing? Report it on the PFE page.
See PFE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PFE catalysts and pipeline →